Abstract
Objective:To investigate the effects of high-dose recombinant human growth hormone(rhGH) treatment on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels in patients with idiopathic dwarfism.Methods:This study retrospectively investigated records of idiopathic dwarfism patients treated at Anhui Children’s Hospital or the Affiliated Hospital of Xuzhou Medical University between May 2019 and October 2020. The study identified 76 patients, which were divided based on rhGH treatment dosage into high- and low-dose groups.Results:The high-dose group showed a total efficacy of 95.3%, which was significantly higher than the 79.41% observed in the low-dose group (P<0.05). Moreover, height, weight, IGF-1 levels, and IGFBP-3 levels were all significantly elevated in the high-dose group compared to the low-dose group (P<0.05). No significant difference in adverse reaction incidence was observed between high- (9.5%) and low-dose (8.8%) groups (P>0.05).Conclusions:Higher doses of rhGH can provide improved curative effects in patients with idiopathic short stature, likely via elevated levels of IGF-1 and IGFBP-3.
Highlights
Idiopathic dwarfism is defined as height that is below the 3rd percentile or is two standard deviations below the median for healthy age, gender, and racematched children.[1]
This study retrospectively examined records of 76 pediatric patients with idiopathic dwarfism treated at Anhui Children’s Hospital (46 cases) or the Affiliated Hospital of Xuzhou Medical University (30 cases) between May 2019 and October 2020
This study found that the clinical efficacy and insulin-like growth factor level of the high-dose group were significantly better than those of the low-dose group
Summary
Idiopathic dwarfism is defined as height that is below the 3rd percentile or is two standard deviations below the median for healthy age, gender, and racematched children.[1]. Idiopathic dwarfism seriously affects pediatric physical and mental well-being and is accompanied by social and psychological problems ranging from decreased learning to elevated suicide risk. Pathogenic causes for idiopathic dwarfism are not clear, and no consensus treatment practice has been established.[2]. Recent research has identified the human growth factor (HGF)-insulin-like growth factor (IGF) neuroendocrine axis as a pathway of interest. This signaling axis can affect growth and development through abnormal modulation of HGF levels.[3]. Pak J Med Sci March - April 2022 (Part-II) Vol 38 No 4 www.pjms.org.pk 1038
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
